Endosense Completes Enrollment in TOCCASTAR IDE Study of Its TactiCath® Force-Sensing Ablation Catheter

Published: Jun 13, 2012

GENEVA--(BUSINESS WIRE)--Endosense,a pioneer and leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced enrollment completion in the TOCCASTAR clinical study. TOCCASTAR is a prospective, randomized, multi-center investigational device exemption (IDE) trial designed to evaluate the safety and effectiveness of the company’s TactiCath force-sensing ablation catheter in patients with symptomatic paroxysmal atrial fibrillation (AF).

Back to news